Activist investor Starboard met with Pfizer last week. Here's what went down, according to the hedge fund's cofounder and CEO ...

Jeff Smith, Starboard Value CEO, joins CNBC's 'Squawk on the Street' to discuss how he sees Pfizer going forward, potential ...

Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the ...

Starboard has a $1 billion stake in Pfizer and an unknown but "sizable" stake in Kenvue, according to earlier media reports.

Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...

Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job.

Failed to import article template. Reason: Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app ...

Jeff Smith says pharma giant’s returns from recent efforts are ‘not adequate’ in speech at 13D activist investor conference ...

but Pfizer's share price and revenues have tumbled from the record highs achieved during the pandemic's heights, and Starboard, led by its 52-year-old cofounder, Jeff Smith, has a long history of ...

Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its ...

Activist hedge fund Starboard Value believes the root cause of Pfizer’s issues are the low expected returns on its research and development investments, including investments done both internally and ...

Since 2011, Starboard Value's Jeff Smith has extracted board seats and profits from corporate America — by force if necessary ...